Cynapsus rethink Apomorphine delivery for Parkinson’s

https://i2.wp.com/static.cdn-seekingalpha.com/uploads/2014/4/282594_13975738559788_0_thumb.jpg
Apomorphine faster-acting than other ‘anti-freeze’ drugs

Cynapsus Therapeutics are currently in stage 3 of trials testing their Apomorphine drug and I could refer to it as a ‘successful failure’. The drug itself does not work for everyone, but for those that do respond positively, it is very very good (I know because I use it myself). The ‘failure’, if you can call it that, is not the drug itself but the delivery system – a pen similar to a diabetic’s pen with tiny needles to inject yourself. At times the injection is hardly felt but at other times it feels like a beesting – that and the acidity of the drug make long-term injections likely to leave scar tissue behind.

cynaf61915-8
the Apokyn Pen, used for apomorphine injections

So, what does Apomorphine do? Well, despite its name there is no narcotic affect so no fun to balance with the pain! The drug is a very fast acting medicine for changing an ‘off’ state to an ‘on’ state – in my own case it averages 5 minutes to take me from a slumped basket case in the mornings to fully switched-on and good to go! It is a subcutaneous rescue therapy (and it has rescued me quite a few times now when I have gone off while out and about) injecting into skin and fat and it is this delivery system which will hopefully be replaced by the current trial version – a sublingual strip that dissolves under your tongue.

There are 2 studies planned – the first will require 126 volunteers for 12 weeks (eligible if you go off at least once each day with a total off time of at least 2 hours daily). After the 12 weeks the participants can join the second study which will require 226 volunteers for 6 months with the same eligibility criteria (The Michael J Fox Foundation will be running a sub-study using a smartphone app to collect data).

The 12 week trial seems to be all in the USA however the 6 month trial is recruiting in the UK as well – the trial number is NCT02542696 and the list following below is for anyone who may be interested in volunteering:

Kings College, The Maurice Wohl Neuroscience Institute
London, Greater London, United Kingdom
Contact: Lauren Perkins    (+44) 203 299 7154
Manchester University Recruiting
Salford, Greater Manchester, United Kingdom, M68HD
Contact: Nessa Thomas    (+44)161 206 7569
Newcastle University Recruiting
Newcastle-upon-Tyne, Northumberland, United Kingdom, NE4 5PL
Contact: Helen Pilkington    +44191 2081250
Forth Valley Royal Hospital Recruiting
Larbert, Stirlingshire, United Kingdom, FK54WR
Contact: David Thomson    (+44)1324 566 230
Fairfield General Hospital Recruiting
Bury, United Kingdom, BL9 7TD
Contact: Paula Mulligan    (+44)161 922 3217
Royal Devon & Exeter NHS Foundation Trust Recruiting
Exeter, United Kingdom, EX2 5DW
Contact: Robert James    (+44)1392 408 145
Queen Elizabeth University Hospital Recruiting
Glasgow, United Kingdom, G51 4TF
Contact: Alison Smith    +44 141 201 2486
Leeds Teaching Hospitals NHS Trust Recruiting
Leeds, United Kingdom, LS1 3EX
Contact: Jane Alty
Contact    1133925073
Imperial College Healthcare Trust NHS Recruiting
London, United Kingdom, W68RF
Contact: Gita Sharma    ( +44) 203 311 1714
Plymouth University Recruiting
Plymouth, United Kingdom, PL6 8DH
Contact: Catherine Harden    (+44)1752 431 807
Sponsors and Collaborators
Sunovion
Investigators
Study Director: CNS Medical Director Sunovion

  More Information

Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT02542696     History of Changes
Other Study ID Numbers: CTH-301  2016-000637-43
Study First Received: September 3, 2015
Last Updated: January 6, 2017

MC

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s